---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-26-000040"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2026-06-08T11:05:51+00:00"
generated_at: "2026-06-08T11:12:14.610952+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B

## Summary
- Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.
- Star receives $1.25B upfront; up to $750M in sales milestones for total consideration of $2.0B.
- VGA039 has Breakthrough Therapy, Fast Track, and orphan drug designations from FDA; Phase 3 VIVID-6 trial ongoing.
- Transaction approved by both boards; expected to close in Q3 2026 subject to HSR review.
- Incyte expects a ~$1.25B R&D charge in Q3 and full year 2026 GAAP and non-GAAP results.

## SEC filing metadata
- accession: 0000879169-26-000040
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2026-06-08T11:05:51+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/0000879169-26-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/incy-20260608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-26-000040
- JSON: https://secwatch.observer/filing/0000879169-26-000040.json
- Plain text: https://secwatch.observer/filing/0000879169-26-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.